Characteristics of the Study Group (N = 109)
| Characteristic . | Category . | No. (%) . |
|---|---|---|
| Age (yr) | >50 | 30 (28) |
| Gender | Male | 75 (69) |
| Hemoglobin (g/dL) | <10 | 24 (22) |
| Platelets (×109/L) | <100 | 3 (3) |
| >450 | 39 (36) | |
| WBC count (×109/L) | >50 | 71 (65) |
| CML phase | Early chronic | 82 (75) |
| Late chronic | 11 (10) | |
| Accelerated | 12 (11) | |
| Blastic | 5 (5) | |
| Additional chromosomal abnormality other than Ph | Yes | 13 |
| Prognostic risk group (early chronic phase only) | Good Intermediate Poor Unknown | 38 (46) 24 (29) 10 (12) 10 (12) |
| Characteristic . | Category . | No. (%) . |
|---|---|---|
| Age (yr) | >50 | 30 (28) |
| Gender | Male | 75 (69) |
| Hemoglobin (g/dL) | <10 | 24 (22) |
| Platelets (×109/L) | <100 | 3 (3) |
| >450 | 39 (36) | |
| WBC count (×109/L) | >50 | 71 (65) |
| CML phase | Early chronic | 82 (75) |
| Late chronic | 11 (10) | |
| Accelerated | 12 (11) | |
| Blastic | 5 (5) | |
| Additional chromosomal abnormality other than Ph | Yes | 13 |
| Prognostic risk group (early chronic phase only) | Good Intermediate Poor Unknown | 38 (46) 24 (29) 10 (12) 10 (12) |